Rutherford Diagnostics and Philips Agree 10 Year Partnership to Improve Diagnostic Services and Patient Outcomes Across England

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) a leading global health technology company, has announced it signed a 10-year strategic partnership agreement with Rutherford Diagnostics. This collaboration will utilize Philips innovative radiology technology and Rutherford Diagnostics' healthcare expertise to deliver and operate advanced personalized diagnostic services through a network of community diagnostic centers, driving the best possible healthcare outcomes for patients. Rutherford Diagnostics is a subsidiary of Proton Partners International which operates diagnostic and cancer centers across the United Kingdom.

The agreement has a term of 10-years and the two organizations will work in partnership to deliver advanced diagnostics services, through five new diagnostics centers across the UK. Under the terms of the agreement, which is built around a Managed Technology Service, Philips will deliver: state-of-the-art imaging equipment provision; management and technology utilization reporting; continuous training; and a research and innovation program.

"For Philips, a successful managed service uses technology as an enabler to drive improved clinical practices and patient outcomes through innovation and sustainability," said Stephen McMillan, Solutions Lead for Philips in the UK. "We believe this partnership with Rutherford Diagnostics is an opportunity to deliver a truly patient-centric diagnostic service with high levels of staff satisfaction. Philips already has a number of innovative managed service agreements with NHS partners here in the UK, so this is an exciting expansion of this service for us, as we partner with our first private provider."

Philips and Rutherford Diagnostics will help expand access to diagnostic services for local patients in a cost-effective way that supports the best possible patient outcomes and experiences.

"Our focus is to change the current healthcare paradigm from a reactive model which responds to disease, to one that is proactive and preventative with far reaching long-term benefits," said Dr Steven Powell, Chief Executive Officer of Rutherford Diagnostics. "We required a strategic partner who will complement our diagnostic service offering with technological innovation. Philips is closely aligned to our vision and can manage complexity while remaining flexible and is the right partner to support us on this journey."

The first three community diagnostic centers are due to go live in 2020, with the remaining two in 2021. The first site is expected to welcome patients in Liverpool in 2020.

About Royal Philips

About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries.

About Rutherford Diagnostics

Rutherford Diagnostics was established to fulfil a much-needed requirement for more advanced diagnostics services. We are developing a network of diagnostics centres across the UK to instigate change from the current reactive paradigm which often results in late stage diagnosis - to a proactive paradigm of prediction, prevention and earliest possible detection of disease. Our philosophy is to strive for world class quality care and we believe getting the basics of care right every time means the right diagnosis first time to ensure the best outcomes. By providing state of the art facilities and advanced clinical equipment we offer the highest level of efficiency and diagnostic yield, we can offer safe and clinically effective services with compassion and sensitivity for outstanding patient experience.

Most Popular Now

AI-Powered CRISPR could Lead to Faster G…

Stanford Medicine researchers have developed an artificial intelligence (AI) tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help...

Groundbreaking AI Aims to Speed Lifesavi…

To solve a problem, we have to see it clearly. Whether it’s an infection by a novel virus or memory-stealing plaques forming in the brains of Alzheimer’s patients, visualizing disease processes...

AI Spots Hidden Signs of Depression in S…

Depression is one of the most common mental health challenges, but its early signs are often overlooked. It is often linked to reduced facial expressivity. However, whether mild depression or...

ChatGPT 4o Therapeutic Chatbot 'Ama…

One of the first randomized controlled trials assessing the effectiveness of a large language model (LLM) chatbot 'Amanda' for relationship support shows that a single session of chatbot therapy...

AI Tools Help Predict Severe Asthma Risk…

Mayo Clinic researchers have developed artificial intelligence (AI) tools that help identify which children with asthma face the highest risk of serious asthma exacerbation and acute respiratory infections. The study...

AI Model Forecasts Disease Risk Decades …

Imagine a future where your medical history could help predict what health conditions you might face in the next two decades. Researchers have developed a generative AI model that uses...

AI Model Indicates Four out of Ten Breas…

A project at Lund University in Sweden has trained an AI model to identify breast cancer patients who could be spared from axillary surgery. The model analyses previously unutilised information...

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

Smart Device Uses AI and Bioelectronics …

As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called "a-Heal," designed by engineers at the University...

Overcoming the AI Applicability Crisis a…

Opinion Article by Harry Lykostratis, Chief Executive, Open Medical. The government’s 10 Year Health Plan makes a lot of the potential of AI-software to support clinical decision making, improve productivity, and...

Dartford and Gravesham Implements Clinis…

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering using Clinisys ICE. The trust deployed the order communications...